Here, we show that cancer cells with aberrant AKT activation by common PI3K pathway lesions (HER2, PIK3CA, MET) show the opposite drug sensitivity profile with reduced sensitivity to ATP-competitive AKT inhibitors. This evidence concerns the gene ERBB2 and cancer.